echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > First in class oral complement C5aR inhibitor approved in Japan

    First in class oral complement C5aR inhibitor approved in Japan

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Article source: Medical Rubik's Cube Info

    On September 27, ChemoCentryx, Vifor Pharma, and Kissei Pharmaceutical jointly announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved the first-in-class oral small molecule complement C5a receptor inhibitor Tavneos (avacopan) to be marketed
    It is used to treat two main types of anti-neutrophil cytoplasmic autoantibody (ANCA)-related vasculitis: microscopic polyangiitis (MPA) and granuloma with polyangiitis (GPA)
    This is the first time this C5aR inhibitor has been approved globally

    ANCA-related vasculitis is a systemic disease.
    Excessive activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels, causing damage and failure of organs such as kidneys
    At present, the treatment of this disease includes non-specific immunosuppressant (cyclophosphamide or rituximab) treatment and long-term daily daily glucocorticoid (steroid), which may cause major clinical risks, including death from infection

    Avacopan uses a novel and highly targeted mechanism of action in the treatment of ANCA-related vasculitis and other complement-driven autoimmune and inflammatory diseases
    It avoids upstream complement inhibition, does not hinder the production of C5b-9, retains the body's defense mechanism (MAC), and also retains the beneficial functions of the C5L2 pathway

    On July 6 this year, ChemoCentryx announced that the PDUFA target date for avacopan's new drug application in the United States has been extended to October 7, 2021
    The PDUFA date for avacopan NDA application was originally July 7, 2021

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.